A clinical study to evaluate the efficacy and safety of ayurvedic formulations (Capsule and syrup Shwasi) in the management of Tamak Shwas w.s.r. to Bronchial Asthma
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- awaited
研究概览
简要总结
Respiration or breathing in and outis the evidence feature of life. The prevalence of respiratory disorders isincreasing due to increasing pollution, overcrowding and poor hygiene. TamakShawas is a variety of Shwas roga associated with difficulty in breathing.Movement of air through the Pranvaha Sarotas is hampered in thisdisease resulting in the cry of the organ heading towards complete failure forwant of air. Tamak Shwas well known for its episodic and chroniccourse which comes under the life threatening diseases. It is analogous toBronchial Asthma in Modern system of medicine due to similarity in symptoms,pathogenesis, onset, causes and precipitating factors. Tamak shwasis characterized by paroxysmal attacks of breathlessness, cough, coryza and chesttightness, rapid respiration distress due to inability to expectorate andprolonged expiration.
The trial formulation Cap and SyrupShwasi is a partial organic herbomineral preparation taken for clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 20.00 Year(s) 至 60.00 Year(s)(—)
- 性别
- All
入选标准
- •Patients willing for trial.
- •Age between 20 -60 years of either sex.
- •Patients presenting with clinical features of Tamak Shwas/Bronchial Asthma with impaired PFT.
排除标准
- •Patients not willing for the trial or not ready to give informed consent.
- •Patients of age < 20 and above 60 years
- •Patients with Uncontrolled Hypertension and Diabetes mellitus with complications.
- •Patients having malignancy, chronic cardiac illness, hepatic disorders, renal disorders, tuberculosis and other comorbid diseases.
结局指标
主要结局
awaited
时间窗: after every 15 days till completion of the trial
次要结局
- awaited(every 15 days after initiating the therapy till completion of the trial)
